drugset / Trial / NCT05303324

Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults

NCT05303324

Phase 1 Completed 48 enrolled Alexion Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

To assess the relative bioavailability of ALXN1840 administered orally as a single enteric-coated (EC) tablet (reference, Treatment A) versus three EC tablets (test, Treatment B).

Timeline

Start
2019-07-04
Primary completion
2019-10-09
Completion
2019-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TIOMOLIBDATE CHOLINE Small molecule Oral

Indications

No indication recorded.